Compare Cipher Pharmaceuticals, Inc. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 25.10%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 12.64
3
With a growth in Net Profit of 116.61%, the company declared Very Positive results in Jun 25
4
With ROE of 11.37%, it has a fair valuation with a 2.70 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CAD 426 Million (Small Cap)
11.00
NA
0.00%
-0.02
21.99%
2.46
Revenue and Profits:
Net Sales:
17 Million
(Quarterly Results - Dec 2025)
Net Profit:
19 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.81%
0%
15.81%
6 Months
1.15%
0%
1.15%
1 Year
39.4%
0%
39.4%
2 Years
99.28%
0%
99.28%
3 Years
363.89%
0%
363.89%
4 Years
584.43%
0%
584.43%
5 Years
1695.7%
0%
1695.7%
Cipher Pharmaceuticals, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.49%
EBIT Growth (5y)
7.12%
EBIT to Interest (avg)
12.64
Debt to EBITDA (avg)
0.38
Net Debt to Equity (avg)
0.17
Sales to Capital Employed (avg)
0.29
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
37.30%
ROE (avg)
25.10%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
2.46
EV to EBIT
18.40
EV to EBITDA
12.78
EV to Capital Employed
2.49
EV to Sales
6.00
PEG Ratio
0.08
Dividend Yield
NA
ROCE (Latest)
13.52%
ROE (Latest)
21.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Sep 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
17.00
17.70
-3.95%
Operating Profit (PBDIT) excl Other Income
8.40
9.30
-9.68%
Interest
0.20
0.30
-33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
18.60
7.60
144.74%
Operating Profit Margin (Excl OI)
343.90%
387.60%
-4.37%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -3.95% vs -4.32% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 144.74% vs -7.32% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
70.50
45.70
54.27%
Operating Profit (PBDIT) excl Other Income
33.20
12.50
165.60%
Interest
1.60
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
38.20
15.80
141.77%
Operating Profit Margin (Excl OI)
327.30%
153.90%
17.34%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 54.27% vs 59.79% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 141.77% vs -42.55% in Dec 2024
About Cipher Pharmaceuticals, Inc. 
Cipher Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.
Company Coordinates 
Company Details
209 Oak Park Blvd, Suite 501 , OAKVILLE ON : L6H 0M2
Registrar Details






